Precision Diagnosis for the Era of Personalized Medicine
Lin Huang,Kun Qian
DOI: https://doi.org/10.1002/smtd.201900717
IF: 12.4
2020-01-01
Small Methods
Abstract:Healthcare is stepping into the era of personalized approaches, tailoring treatment based on precision disease patterns. Diseases diagnosed at an advanced-stage result in lower survival rates, greater treatment morbidity, and higher healthcare costs. As the first step in personalized medicine, diagnosis aims to characterize diseases on patient-specific information and to intercept diseases early and, ideally, prevent them. Science is getting closer to diagnosing diseases at a very early stage. Taking non-small cell lung cancer (NSCLC) as an example, the five year survival rate will be increased to over 90% for patients diagnosed at the earliest stage (IA), which is only 10% at the metastatic stage. Advances in new diagnostic tools that allow for even greater precision are expected to continue. However, diagnostics have been under-appreciated these days. For example, according to a 2015 National Academy of Medicine report, the delivery of healthcare is facing significant challenges with common diagnostic errors (e.g., inaccurate or delayed diagnosis). In 2015, at least 5% of U.S. outpatients experienced a diagnostic error, and the diagnostic errors contributed to 10% of all patient deaths. More importantly, there are a number of biological and pathological processes that still cannot be analyzed and diagnosed. If personalized medicine moves toward a more preventive and comprehensive model, advanced diagnostic tools are highly demanded globally. This special issue in Small Methods is an ideal platform to disseminate the frontier knowledge generated in the diagnostic field to exemplify this point (Figure 1). We have assembled a selection of ten articles, including two research articles and eight reviews. Tracing along the typical operational procedures of medical diagnosis, similar innovations are included in this special issue, such as novel material preparation, device engineering, detection methods, and biomedical applications. For novel material preparation, Prof. Huan-Tsung Chang and co-workers (article number 1900387) outline recent advances of carbon (C) dots, emphasizing their applications in sensing and imaging. They first describe the preparation and bioconjugation of C dots from various carbon precursors, focusing on common bottom-up synthetic routes including hydrothermal, microwave-assisted, and electrochemical methods. Strategies for tuning the optical properties of C dots are discussed, particularly for the preparation of C dots with strong fluorescence intensity in the visible and near-infrared (NIR) regions. Theories about the fluorescence of C dots are provided to pave the way for the preparation of the desired C dots and the development of highly sensitive sensing systems. Sensing of various analytes, including metal ions, biomolecules, and microorganisms, and both in vitro and in vivo imaging using functional C dots are believed to be of great potential toward biodiagnostics. Prof. Zhuo Chen and co-workers (article number 1900440) discuss the latest progress of multifunctional graphitic nanocapsules in biodiagnostics. This review covers the synthesis, properties, and functionalization of graphitic nanocapsules. The materials have long been used in Raman detection and imaging, multimodal imaging, and light-mediated therapy. For future clinical applications, the biocompatibility and toxicology profiles of graphitic nanocapsules in biological systems is a vital issue that must be addressed. The authors summarize that negligible cytotoxicity occurs in cells and major organs within a certain dose range of graphitic nanocapsules. For device engineering, Prof. Xingyu Jiang and co-workers (article number 1900451) review the recent advances in microfluidics for biomedical analysis. Microfluidics consumes minimum samples and reagents and can precisely control the flows. Conjugating with the possibilities for assay automation and integration, microfluidics gives rise to replace a typical clinical lab, especially in point-of-care (POC) testing. The authors highlight the detection of proteins, nucleic acids, single cells, specific organs, and clinically important small molecules in various biological fluids. They further show the applications of microfluidics in biology, clinical diagnosis, food safety, and environmental monitoring. The applications of microfluidic techniques in pathogen and cancer detection are underscored in detail. As a developmental perspective, the authors predict four directions worthy for further investigation, including integrated nucleic acids analysis; simultaneous analysis of nucleic acids, proteins, and other biomarkers; truly POC testing; and integration with nanotechnology and new materials. Another method to achieve POC testing is the equipment-free quantitative readout in paper-based devices. The review by Prof. Feng Xu and co-workers (article number 1900459) stress the fabrication strategies for paper-based POC testing, including highlighting distance-based, counting-based, time-based, and text-based strategies. Each strategy detects a variety of analytes for different applications, such as proteins, nucleic acids, metal ions, and cells. The authors make a detailed comparison of four strategies, such as integration, analysis time, limit of detection, and detection range. Although these equipment-free strategies have exhibited acceptable performance in the lab, drawbacks still existed in practical applications, for instance, unexpected pretreatment, low reproducibility, and insufficient detection sensitivity. The authors propose three ways to achieve the real case POC testing, including performing more fundamental work to improve the performance of devices; designing reaction systems to produce easily detectable analytes; and developing new equipment-free strategies through converting detection signals to other naked eye–distinguished signals. For detection methods, recent developments of high-throughput technologies shed light on the molecular-level analysis and bioinformatic mining of genes and metabolites. These approaches explore either the sequence of circulating cell-free DNA (cfDNA) using next-generation sequencing (NGS) or serum metabolomics analysis using mass spectrometry. In article number 1900357, Prof. Jiatao Lou's group develops a novel amplicon-based NGS technology, CLAmp-seq (circular ligation amplification and sequencing), to enhance the sensitivity and specificity of cfDNA detection in NSCLC patients. They propose a concatemer-based error correction strategy, which can effectively remove polymerase errors from the first round of amplification. The authors further applied CLAmp-seq NGS to the analysis of 134 NSCLC patient plasma samples, demonstrating strong concordance (97.4%) and linearity (R2 = 0.95) between the CLAmp-seq NGS readouts and droplet digital PCR (ddPCR) results. They forecast that the assay as an accurate molecular diagnostic tool is well-suited for clinical liquid biopsy. The occurrence and development of diseases involve complex regulation mechanisms. The current detection of single biomarkers hardly depicts a comprehensive picture of disease status under the context of personalized medicine. The path of technological progress now takes us to dimensions of “omics”. Spectrometric methods, particularly mass spectrometry (MS), enjoy high-throughput extraction and measurement of omics, while tandem MS allows accurate identification of molecules. The technological advancements in MS, combined with artificial intelligence, are ushering in a new era of advanced diagnostics that will transform the understanding and treatment of various diseases. The work by Prof. Jingjing Wan's group (article number 1900469) might give it a head start. The authors construct a plasmonic chip for metabolomic analysis. The surface roughness and Au content of the designed chip are optimized to enable fast, sensitive, and selective detection of small metabolites in human serum without any enrichment or purification. In addition, they combine the obtained metabolic fingerprints with multivariate statistical analysis to diagnose cervical cancer from control subjects. For potential clinical monitoring, they further achieve the therapeutic evaluation for certain differentially expressed biomarkers. Another work concerning the updated and essential development of MS is the review by Prof. Yu Bai and co-workers (article number 1900407). Their interest in MS is in situ analysis of biomarker molecules for clinical diagnosis. The authors summarize laser-based, spray-based, plasma-based, and intrasurgical MS techniques based on the detection mechanisms and real case applications. The group proposes that some obstacles and challenges should be addressed before implementation of MS methods in clinical laboratories, including the design of portable sampling devices, the introduction of miniature MS instrumentation, the development of high-throughput, and multiplexed methodologies. In total, they argue the in situ MS analysis requires no or little sample pretreatment, which offers access for large scale diagnostic applications. For suitable biomedical applications, booming progress has been witnessed both for in vivo and in vitro diagnosis in the last decades. Prof. Jianfeng Liu and co-workers (article number 1900403) review the latest results of self-assembled peptide-based nanoprobes for in vivo disease theranostics and disease-related molecular imaging. The review starts from the progress of self-assembled peptide-based nanoprobes for diagnostics, including cancer detection, bacterial infection diagnosis, and other diseases. They also comment on the application potency of nanoprobes in disease-related molecular detection, such as caspases, matrix metalloproteinase (MMP-9), γ-glutamyltranspeptidase, and Tip-1, etc. Except for enzymes, the self-assembled peptide-based nanoprobes are explored to detect metal ions, cysteine, and protein thiols. The advances in cell imaging are revealed in this review with the specific emphasis on membrane dynamic imaging. The authors consider several limitations need to be resolved when translating those approaches into practical applications, such as fast renal clearance, poor stability, and inferior selectivity and sensitivity in vivo. In article number 1900583, Prof. Lei Zheng and co-workers give an outlook of the prospects of bringing aggregation-induced emission luminogen (AIEgens) into imaging studies at the in vivo level. The aggregation-caused quenching (ACQ) effect is the major concern that hinders the applications of conventional organic dyes in living animals. The advent of aggregation-induced emissions offers a new strategy to deal with ACQ, due to the restricted intramolecular motion. The authors showcase the recent applications of AIEgens in the clinical aspects, such as in vivo vascular and tumor-targeted imaging, monitoring biological processes, disease diagnosis, and image guided therapy. Efforts awaited for the future exploration are increasing tissue-penetration depth, improving imaging quality, developing novel AIE-based theranostic systems, establishing a closer relationship between basic research and clinicians, and evaluating biosafety issues of AIEgens. Other than in vivo practice, Prof. Ming Chen and co-workers (article number 1900506) focus on in vitro diagnosis based on micro-nano technologies, including microchip-based devices, DNA nanomachines, and DNA nanomaterials. For microchip-based devices, terahertz and surface acoustic wave sensing have been vastly applied in the analysis of nucleic acids, proteins, cells, and chemicals, thanks to the ultrasensitive, label-free, amplification-free, and robust detection capability. For DNA nanomachines, DNA tweezers, robots, and walkers have been utilized as functional sensing interfaces for detection, especially when combined with microchip-based devices. In addition, DNA nanomachines for target sensing have been discussed, involving DNA aptamers, DNAzymes, and hybrid DNA nanomaterials. The authors believe if the current limitations (e.g., high cost of micro–nano fabrication and the lack of stability of DNA nanomachines in complex matrix) can be addressed, the micro–nano technologies will play a critical role in the next generation diagnostics. In summary, the underpinnings of a greater emphasis on diagnostics will be advanced tools that can decode disease. The emerging diagnostic assays highlighted in this special issue demonstrate proof-of-concept evidence that rational design can enable better diagnosis, potentially revolutionizing healthcare in the coming era of personalized medicine. However, we still need to note that, in addition to performance parameters in the lab such as sensitivity, specificity, and speed, the search for a viable commercial application is still awaited for clinical use. Thus, this special issue provides significant ideas and guidance for the development of next generation diagnostic tools. Lin Huang received her Ph.D. in biomedical engineering from Shanghai Jiao Tong University, China. Currently, she is a senior research fellow at Renji Hospital, School of Medicine, Shanghai Jiao Tong University, China. Her research interests focus on the development of novel materials for in vitro diagnostics based on laser desorption/ionization mass spectrometry (LDI MS). Kun Qian received his B.S./M.S. from Fudan University, his Ph.D. from the University of Queensland, and held the position of Research Fellow at Stanford University. He is now a principle investigator (PI) in the School of Biomedical Engineering, Shanghai Jiao Tong University. His research interests and efforts are on design, synthesis, and engineering of materials and devices. His group aims at the development and commercialization of bioanalytical methods and mass spectrometry techniques for diverse biomolecules in biomedical application.